vs
碧迪（BDX）与Equitable Holdings, Inc.（EQH）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是Equitable Holdings, Inc.的1.6倍（$5.3B vs $3.3B），碧迪净利率更高（7.3% vs 6.6%，领先0.7%），碧迪同比增速更快（-0.4% vs -9.5%），过去两年Equitable Holdings, Inc.的营收复合增速更高（21.2% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
Equitable Holdings, Inc.是美国领先的金融服务与保险企业，1859年由亨利·鲍德温·海德创立，业务覆盖保险、财富管理等多元金融领域，拥有逾百年发展历史，在全球金融服务市场具备深厚的行业积淀与广泛的客户基础。
BDX vs EQH — 直观对比
营收规模更大
BDX
是对方的1.6倍
$3.3B
营收增速更快
BDX
高出9.1%
-9.5%
净利率更高
BDX
高出0.7%
6.6%
两年增速更快
EQH
近两年复合增速
2.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $3.3B |
| 净利润 | $382.0M | $215.0M |
| 毛利率 | 45.9% | — |
| 营业利润率 | 10.5% | 10.5% |
| 净利率 | 7.3% | 6.6% |
| 营收同比 | -0.4% | -9.5% |
| 净利润同比 | 24.0% | -76.1% |
| 每股收益（稀释后） | $1.34 | $0.69 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXEQH
| Q4 25 | $5.3B | $3.3B | ||
| Q3 25 | $5.9B | $1.4B | ||
| Q2 25 | $5.5B | $2.4B | ||
| Q1 25 | $5.3B | $4.6B | ||
| Q4 24 | $5.2B | $3.6B | ||
| Q3 24 | $5.4B | $3.1B | ||
| Q2 24 | $5.0B | $3.5B | ||
| Q1 24 | $5.0B | $2.2B |
净利润BDXEQH
| Q4 25 | $382.0M | $215.0M | ||
| Q3 25 | $493.0M | $-1.3B | ||
| Q2 25 | $574.0M | $-349.0M | ||
| Q1 25 | $308.0M | $63.0M | ||
| Q4 24 | $303.0M | $899.0M | ||
| Q3 24 | $400.0M | $-134.0M | ||
| Q2 24 | $487.0M | $428.0M | ||
| Q1 24 | $537.0M | $114.0M |
毛利率BDXEQH
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 45.7% | — |
营业利润率BDXEQH
| Q4 25 | 10.5% | 10.5% | ||
| Q3 25 | 11.8% | -93.0% | ||
| Q2 25 | 16.0% | -15.4% | ||
| Q1 25 | 10.4% | 3.8% | ||
| Q4 24 | 8.8% | 33.1% | ||
| Q3 24 | 11.4% | -0.5% | ||
| Q2 24 | 12.1% | 19.4% | ||
| Q1 24 | 14.5% | 11.1% |
净利率BDXEQH
| Q4 25 | 7.3% | 6.6% | ||
| Q3 25 | 8.4% | -90.3% | ||
| Q2 25 | 10.4% | -14.8% | ||
| Q1 25 | 5.8% | 1.4% | ||
| Q4 24 | 5.9% | 24.8% | ||
| Q3 24 | 7.4% | -4.4% | ||
| Q2 24 | 9.8% | 12.2% | ||
| Q1 24 | 10.6% | 5.1% |
每股收益（稀释后）BDXEQH
| Q4 25 | $1.34 | $0.69 | ||
| Q3 25 | $1.71 | $-4.47 | ||
| Q2 25 | $2.00 | $-1.21 | ||
| Q1 25 | $1.07 | $0.16 | ||
| Q4 24 | $1.04 | $2.72 | ||
| Q3 24 | $1.37 | $-0.47 | ||
| Q2 24 | $1.68 | $1.23 | ||
| Q1 24 | $1.85 | $0.30 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $12.5B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $25.3B | $-74.0M |
| 总资产 | $54.8B | $318.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BDXEQH
| Q4 25 | $740.0M | $12.5B | ||
| Q3 25 | $641.0M | $13.6B | ||
| Q2 25 | $735.0M | $15.0B | ||
| Q1 25 | $667.0M | $8.2B | ||
| Q4 24 | $711.0M | $7.0B | ||
| Q3 24 | $1.7B | $9.6B | ||
| Q2 24 | $4.5B | $9.7B | ||
| Q1 24 | $2.3B | $10.4B |
股东权益BDXEQH
| Q4 25 | $25.3B | $-74.0M | ||
| Q3 25 | $25.4B | $148.0M | ||
| Q2 25 | $25.5B | $1.1B | ||
| Q1 25 | $25.2B | $2.4B | ||
| Q4 24 | $25.2B | $1.6B | ||
| Q3 24 | $25.9B | $3.2B | ||
| Q2 24 | $25.9B | $1.6B | ||
| Q1 24 | $25.6B | $2.0B |
总资产BDXEQH
| Q4 25 | $54.8B | $318.0B | ||
| Q3 25 | $55.3B | $314.4B | ||
| Q2 25 | $54.9B | $303.1B | ||
| Q1 25 | $54.5B | $287.4B | ||
| Q4 24 | $54.7B | $295.9B | ||
| Q3 24 | $57.3B | $299.0B | ||
| Q2 24 | $55.6B | $287.8B | ||
| Q1 24 | $54.2B | $285.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $-154.0M |
| 自由现金流经营现金流 - 资本支出 | $549.0M | — |
| 自由现金流率自由现金流/营收 | 10.5% | — |
| 资本支出强度资本支出/营收 | 2.1% | — |
| 现金转化率经营现金流/净利润 | 1.72× | -0.72× |
| 过去12个月自由现金流最近4个季度 | $2.6B | — |
8季度趋势，按日历期对齐
经营现金流BDXEQH
| Q4 25 | $657.0M | $-154.0M | ||
| Q3 25 | $1.4B | $369.0M | ||
| Q2 25 | $1.2B | $341.0M | ||
| Q1 25 | $164.0M | $158.0M | ||
| Q4 24 | $693.0M | $400.0M | ||
| Q3 24 | $1.2B | $683.0M | ||
| Q2 24 | $1.3B | $892.0M | ||
| Q1 24 | $514.0M | $31.0M |
自由现金流BDXEQH
| Q4 25 | $549.0M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $35.0M | — | ||
| Q4 24 | $588.0M | — | ||
| Q3 24 | $882.0M | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $380.0M | — |
自由现金流率BDXEQH
| Q4 25 | 10.5% | — | ||
| Q3 25 | 17.0% | — | ||
| Q2 25 | 19.0% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 11.4% | — | ||
| Q3 24 | 16.2% | — | ||
| Q2 24 | 22.4% | — | ||
| Q1 24 | 7.5% | — |
资本支出强度BDXEQH
| Q4 25 | 2.1% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 2.0% | — | ||
| Q3 24 | 5.4% | — | ||
| Q2 24 | 3.6% | — | ||
| Q1 24 | 2.7% | — |
现金转化率BDXEQH
| Q4 25 | 1.72× | -0.72× | ||
| Q3 25 | 2.75× | — | ||
| Q2 25 | 2.12× | — | ||
| Q1 25 | 0.53× | 2.51× | ||
| Q4 24 | 2.29× | 0.44× | ||
| Q3 24 | 2.94× | — | ||
| Q2 24 | 2.66× | 2.08× | ||
| Q1 24 | 0.96× | 0.27× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
EQH
| Other | $1.5B | 46% |
| Asset Management | $1.2B | 37% |
| Wealth Management | $545.0M | 17% |
